The Clinical Investigation of a Toothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity - an Eight-week Clinical Study in the US

The objective of this study is to assess clinical efficacy of a toothpaste containing 8% arginine (Colgate-Palmolive Company, New York, NY, USA) to provide dental hypersensitivity relief (tactile and air blast) in comparison to Colgate Cavity Protection Toothpaste (Colgate-Palmolive Company, New York, NY, USA) over an eight-week period.

Start Date14 Jul 2025

Sponsor / Collaborator

Colgate-Palmolive Co.

IRCT20160130026260N5

/ RecruitingPhase 2

The effect of L-arginine in fetuses with intrauterine growth restriction, on Doppler ultrasound and fetal biometry indices and infant complications

Start Date05 Nov 2024

Sponsor / Collaborator

Shiraz University of Medical Sciences

CTRI/2024/10/075848

/ Not yet recruitingPhase 4IIT

A Comparative Clinical Study of Yashtimadhu, Gambhari Siddha Ksheerpaan And L- Arginine in Garbhashosha With Special Reference to Asymmetrical IUGR - NIL

Start Date01 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Arginine

100 Translational Medicine associated with Arginine

100 Patents (Medical) associated with Arginine

92,700

Literatures (Medical) associated with Arginine

01 Feb 2026·JOURNAL OF COLLOID AND INTERFACE SCIENCE

A dual-drug delivery hydrogel platform based on hollow calcium carbonate nanoparticles for enhanced multimodal tumor therapy

Article

Author: Li, Weibo ; Zhou, Jian ; Gong, Yi ; Qi, Qiang ; Wei, Haoyu ; Li, Jin ; Zhao, Xiaofeng ; Wang, Ting ; Yao, Haoge ; Wang, Hongdi

Multimodal cancer therapies that integrate gas and photodynamic approaches hold significant promise but are often limited by low drug loading rates, short treatment durations, and suboptimal overall therapeutic efficacy. In this study, we developed hollow calcium carbonate nanoparticles via a one-pot gas-diffusion approach, employing rational selection and concentration tuning of amino acid additives to regulate particle formation. Notably, by utilizing L-arginine as a regulating agent, we produced nanoparticles with a significant specific surface area of 197.96 m²/g. Subsequent PEGylated/liposomal surface modification endowed the nanoparticles with excellent biocompatibility and an impressive drug loading capacity of up to 28.8 % and 26.9 % for the nitric oxide donor L-arginine and the photosensitizer indocyanine green (ICG), respectively. The resulting drug-loaded hollow amorphous calcium carbonate nanoparticles (PCAI NPs) have shown effective synergistic treatment against tumors through multimodal therapy methods, including photodynamic therapy, nitric oxide gas therapy, photothermal therapy, and calcium overload-induced cytotoxicity. Furthermore, PCAI NPs were encapsulated in an injectable thermo-responsive hydrogel system composed of Pluronic F-127 and hyaluronic acid, creating a nano drug delivery system that enables sustained, prolonged, and localized drug release. This work presents a high-loading, multifunctional nanoplatform for enhanced and prolonged multimodal cancer therapy.

01 Feb 2026·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Bismuth-based dissolvable microneedle: A precision-targeted “surgical scalpel” for dual-gas synergistic tumor therapy

Article

Author: Yang, Zhuoran ; Xu, Mengshu ; Yang, Chunyu ; Guo, Wei ; Li, Yuexin ; Lin, Siqi ; Hu, Tingting

Breast cancer remains the leading cause of cancer-related deaths because conventional therapies are constrained by systemic toxicity, insufficient specificity, and low patient adherence to patients. In this study, we developed a dissolvable microneedle (MN) platform integrating Bi/Bi₂SiO₅@SiO_2-x nanocomposites with gaseous prodrugs L-arginine (L-Arg) and ammonia borane (AB) for imaging-guided synergistic therapy. Bi-based nanocomposites exhibit strong near-infrared (NIR) absorption, efficient singlet oxygen (¹O₂) generation, and high X-ray attenuation, enabling effective tumor ablation and real-time computed tomography (CT) imaging. An appropriately designed SiO_2-x shell not only protects Bi from oxidation and prevents performance degradation but also efficiently captures the energy transferred from Bi, further facilitating ¹O₂ generation. The L-Arg and AB incorporated into the dissolvable MNs achieved a pH-responsive release of NO and H₂ following transdermal absorption, thereby enhancing photothermal, photodynamic, sonodynamic, and dual-gas synergistic therapies under NIR and ultrasound stimulation. In vitro and in vivo experiments confirmed its potent antitumor efficacy, outstanding biocompatibility, and minimal invasiveness. This study introduces a multifunctional therapeutic platform that addresses the key limitations of breast cancer therapy, offering a precise and non-invasive treatment strategy.

01 Feb 2026·BIOMATERIALS

Nitric oxide-driven copper homeostasis and osteogenesis in cranial defect regeneration using l-arginine-loaded HKUST-1

Article

Author: Wu, Yingying ; Xu, Zhaoyu ; Bai, Fuwei ; Zhou, Feng ; Xiang, Lin ; Wang, Dongyang ; Man, Yi ; Wang, Qingyi

Copper plays a multifaceted role in bone tissue engineering, including regulating osteogenic and chondrogenic differentiation, exhibiting antibacterial activity, and enhancing mechanical properties. However, excessive copper induces a distinctive form of cell death, termed cuproptosis which compromises the biocompatibility of copper-based biomaterials. Cuproptosis relies on oxidative phosphorylation and can be inhibited by the Warburg effect, which is the characteristic of aerobic glycolysis in tumor cells. Therefore, nitric oxide (NO), an endogenous signaling molecule that promotes glycolysis and osteogenesis, may potentially inhibit cuproptosis and promote bone repair in copper-based biomaterials. In this study, a Cu-MOF encapsulating l-arginine was synthesized, capable of sustaining NO release through NOS catalysis and H₂O₂ consumption. It was found to inhibit the cuproptosis and synergistically promote osteogenesis. Multi-omics analyses revealed that this effect is primarily mediated by upregulating glutathione (GSH) synthesis, downregulating the GABA shunt, and enhancing aerobic glycolysis. Furthermore, GelMA loaded with LA@HK was shown to enhance bone defect repair and angiogenesis, and inhibit inflammatory response. Meantime, LA@HK also maintained antibacterial activity and mechanical performance. This therapy may serve as a simple but effective strategy to mitigate copper-induced cytotoxicity and promote osteogenesis, which also provides a novel metabolic mechanism for osteogenesis mediated by NO.

News (Medical) associated with Arginine

12 Nov 2025

·www.prnewswire.com

New Research Finds Dietary Intervention of Peanuts Improves Brain Vascular Function and Memory

ALBANY, Ga., Nov. 12, 2025 /PRNewswire/ -- The Peanut Institute is sharing a recent study from the Institute of Nutrition and Translational Research in Metabolism (NUTRIM) at Maastricht University Medical Center, Maastricht, Netherlands, that found the consumption of unsalted, skin-roasted peanuts can significantly improve brain vascular function and memory. The findings were published online in the international, peer-reviewed journal Clinical Nutrition. Continue Reading Mean cerebral blood flow (CBF) maps following the (A) peanut intervention and (B) control periods in adults (n = 31). CBF displayed in mL100 gmin (scale shown by color bar). To operate effectively and efficiently, the brain relies on a network of blood vessels to supply it with oxygen and nutrients. As people age, vascular brain function can become impaired, contributing to an elevated risk of cognitive decline and dementia. The NUTRIM study of 31 healthy older adults ranging in age from 60-75 observed that consuming 60 grams (approximately a half cup) of peanuts daily for 16 weeks increased global cerebral blood flow (CBF) by 3.6% and verbal memory by 5.8%. In addition to the brain improvements, systolic blood pressure and pulse pressure decreased by 5 mmHg and 4 mmHg, respectively. "CBF is an important physiological marker because having a strong flow of blood to the brain contributes to its health," says Dr. Peter Joris, the study's author and an associate professor in the Department of Nutrition and Movement Sciences, NUTRIM, Maastricht University Medical Center. "We found that longer-term consumption of unsalted, skin-roasted peanuts improved global CBF, which suggests an overall enhancement in brain vascular function." The peanut intervention also resulted in increased blood flow in the frontal and temporal lobes of the brain, both of which are important for memory and other cognitive functions. "Peanuts are especially rich in plant-based protein and contain high concentrations of L-arginine, an amino acid important for vascular health. They are also a valuable source of unsaturated fats and polyphenols, both known to support vascular function," says Joris. "For this study, skin-roasted peanuts were chosen because the peanut skin contains additional dietary fiber and natural plant compounds, specifically antioxidants. Together, these nutrients may help explain the beneficial health effects of skin-roasted peanuts observed in this study." The NUTRIM study is unique because it combined a well-controlled, longer-term dietary intervention with magnetic resonance imaging (MRI), an advanced brain imaging technique, to investigate the effects of daily peanut consumption on brain health. Cognitive performance was evaluated using a computerized system known as the Cambridge Neuropsychological Test Automated Battery (CANTAB). "For the first time, we demonstrated that peanut intake improved brain vascular function in healthy older adults. These favorable effects may help explain the observed improvements in memory, providing novel mechanistic insight into how regular peanut consumption can beneficially affect cognitive function," says Joris. NUTRIM Study Details The study was a randomized, controlled crossover trial - one of the strongest designs in clinical research. Participants in the intervention group were given premeasured packets of skin-roasted peanuts and directed to consume the peanuts in the morning or afternoon. They were allowed to eat the daily amount all at once, spread it out over the day or add the peanuts to their meals. The control group did not consume peanuts. After 16 weeks, the groups switched conditions to further assess the effects of peanut consumption versus no peanuts on brain health. The principal investigator of the study was Associate Professor Dr. Peter J. Joris. Test days were conducted by Ph.D. candidate Lucia Kerkhof, Department of Nutrition and Movement Sciences, Maastricht University Medical Center. The NUTRIM study was supported by funding from The Peanut Institute Foundation. The funder did not have a role in the study design, implementation, analysis or interpretation of the data or the writing of the manuscript. Based in Albany, Ga., The Peanut Institute is a non-profit organization supporting nutrition research and developing educational programs to encourage healthful lifestyles that include peanuts and peanut products. The Peanut Institute pursues its mission through research programs, educational initiatives and the promotion of healthful lifestyles to consumers of all ages. As an independent forum, The Peanut Institute is uniquely positioned to work with all segments of the food industry, the research community, academia, consumer organizations and governmental institutions. SOURCE The Peanut Institute 21% more press release views with Request a Demo

Clinical ResultClinical Study

30 Jul 2025

·www.biospace.com

Opinion: IRA’s Definition of ‘Drug’ Creates Confusion for Developers

Yaraslau Saulevich/ iStock Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price negotiation purposes—even if approved by the FDA under a separate application—disincentivizing companies from investing time and money in gaining approval for new formulations and indications. In January, as expected, the Centers for Medicare and Medicaid Services released the second round of medicines selected for price negotiations under the Inflation Reduction Act of 2022. While CMS highlighted 15 drugs that together account for billions in Medicare Part D spending, the list in fact included 19 distinct brand names and 26 distinct drug products, each approved by the FDA under a separate application. The most notable example is Novo Nordisk’s semaglutide-based offerings, with Ozempic, Wegovy and Rybelsus all being considered a single drug by the government’s definition. This quirk of IRA drug price negotiations raises a concern: while the drug provisions under the IRA could be implemented in such a way that would be a win for some Medicare patients, I fear the agency’s interpretation of the IRA could disincentivize important drug research and end up hurting many of the Medicare recipients it’s meant to protect. Having carefully analyzed the likely effects of these provisions in my capacity as a faculty member in pharmaceutical economics at the University at Utah and as a former CMS advisor, I found that this definition could force manufacturers to abandon research into new products with the same active ingredients as previously approved drugs. A CMS-FDA Disconnect The problem stems from how CMS has interpreted the term “qualifying single source drug” (QSSD). The IRA authorizes government officials to negotiate prices for a fixed number of certain QSSDs covered under Medicare Part B and Part D. CMS has interpreted QSSD to mean any products based on the same active ingredient or core molecule, even if those products were approved under entirely separate applications to the FDA. The FDA often considers drugs that share an active ingredient but are delivered to the body in different ways or have different strengths as fully distinct products requiring separate regulatory approvals. The same can be true of medicines originally approved to treat one condition that later prove effective against a different illness or illnesses. Novo’s blockbuster diabetes drug Ozempic was the company’s first semaglutide product to hit the market, in 2017, followed by Rybelsus, a different form (a pill vs injectable), nearly two years later, and Wegovy, for a different condition (obesity), in 2021. Last year’s drug list from CMS similarly captured more than the 10 products the agency was instructed to identify for the first year of the program. One of the selected QSSDs, insulin aspart, was originally approved in vials and syringes for treatment of diabetes mellitus under a single biologic license application (BLA). After additional research, scientists recognized that by modifying the structure of the insulin aspart molecule to include niacinamide (Vitamin B3) and L-arginine, they could increase its absorption and stability. In 2017, this improved product became the very first available “ultra-rapid acting” therapy under a separate BLA approved by the FDA. The two medicines shared the same generic name but underwent separate clinical trials, required their own FDA applications and are being marketed under different names (Novolog and Fiasp). They are, in other words, two separate drugs, just as Ozempic, Rybelsus and Wegovy are. However, CMS considered them to be the same drug for the purposes of the Medicare Price Negotiation Program. The drugs’ maker, Novo Nordisk, has sued the government over this grouping, arguing that as a result, CMS is negotiating the prices of more drugs than the law allows. The company is right to contest QSSD’s definition, which is making post-approval research far more financially risky. A Disincentive to Pursue Additional Indications Post-approval drug research of the kind Novo performed is common. In fact, of the 155 cancer medicines approved between 2001 and 2021, 57 percent were for post-approval uses or indications. Finding such new uses or developing alternative dosage forms for a particular active ingredient is no cakewalk. It can take years and cost millions of dollars. As such, these subsequent approvals should be provided with the same protections that lawmakers have given to first approvals—specifically, exempting them from price negotiations for nine or 13 years, depending on the type of drug—to ensure developers can recoup their upfront investments. Under CMS’s definition of QSSD, all versions of a given drug are subject to negotiations nine or 13 years after the first formulation is approved—even if that’s only a few years after the drug in question reaches the market. This disincentivizes drug manufacturers from pursuing the research required for new indications. This could significantly impact rare conditions, as researchers found that from 2003 to 2022 the FDA approved follow-on indications for nearly 1 in 4 orphan drugs . It’s not just drugs for rare diseases that are likely to be affected. Much has been written about the promise of the GLP-1 class of medicines, including Novo’s three that were lumped together and selected most recently for negotiation. The active ingredients in this class are showing exciting early promise in a breathtakingly wide array of conditions —from kidney disease to cancer, from Parkinson’s to Alzheimer’s, even addiction. What will lumping together so many potential treatments as a single drug for purposes of Medicare’s drug pricing program do to the incentives to invest in each? Absent a change in CMS’s current definition, efforts to find new drug products, for new indications or with different dosage forms, strengths and routes of administration, will lose momentum. And countless therapies might remain undiscovered. By one estimate , the IRA’s pricing reforms will result in 79 fewer small-molecule drugs and 109 fewer post-approval indications for those same drugs in the next two decades. During the open comment period on the final guidance from CMS, several commentors raised concerns about the overly broad definition of a QSSD. CMS stood firm, stating that its broad QSSD definition would prevent manufacturers from engaging in “product hopping,” where a minor modification of a drug is introduced and demand is shifted from the original drug. But the agency failed to address the concerns about reduced incentives for research on new uses. CMS stated that “the negotiation process aims to reward manufacturers’ innovation and improved benefits across populations” but gave no clear guidance on what that means. To make matters worse, in May, CMS issued guidance for how it might handle QSSDs in 2028. The agency is rethinking the way certain combination drugs are grouped, meaning medicines that include more than one active ingredient. Until now, every combo drug was treated as a separate product when selecting drugs for price negotiation. But under the new guidance, if part of a combo drug doesn’t help treat the disease on its own, CMS might now group it with other drugs that only include the disease-fighting ingredient. This could make some combo drugs more likely to be selected for price negotiation. Here again, CMS is stepping into territory usually handled by the FDA, like deciding whether an ingredient is “ biologically active ” (helps treat the disease). This term isn’t defined in the IRA. There is still time for CMS to bring its definition of QSSD into alignment with the FDA’s practices. In the short term, the new administration should reevaluate the current guidance before price negotiations are fully implemented in 2026 and 2027—and as the 2028 guidance is considered. It’s rare that the federal government can encourage innovation simply by revising its interpretation of a few words. But in this instance, that’s exactly what’s at stake.

Drug Approval

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

100 Deals associated with Arginine

External Link

KEGG	Wiki	ATC	Drug Bank
D02982	-	B05XB01	DB00125

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dentin Sensitivity	Phase 3	United States	Colgate-Palmolive Co.	14 Jul 2025
Dental Caries	Phase 2	United States	Colgate-Palmolive Co.	21 Jan 2021
Dental Caries	Phase 2	Puerto Rico	Colgate-Palmolive Co.	21 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04765644 (ASCENT, CTgov)	Phase 4	-	44	celecoxib+L-arginine (Celecoxib)	hbemksiebu(kiwbozyttq) = vpyymlaxic qkijiqbvcg (hyklogdivp, 0.35) View more	-	28 Oct 2024
				Placebo+L-arginine + placebo (Placebo)	hbemksiebu(kiwbozyttq) = qdbhcokdwt qkijiqbvcg (hyklogdivp, 0.33) View more
NCT01439555 (Pubmed \| Alzheimers Res Ther)	Phase 2	Alzheimer Disease	11	Simvastatin	dzyhtckqkf(phowmcqtgy) = enmyjjviue vvyapphwfl (isuenokeaw )	-	17 Sep 2022
				L-arginine	dzyhtckqkf(phowmcqtgy) = emiucfdxgb vvyapphwfl (isuenokeaw )
NCT02536170 (CTgov)	Phase 2	Venoocclusive disease \| Anemia, Sickle Cell	108	L-arginine (L-Arginine)	iceownkqva(qivsjupmji) = jniektvboe bbpefrpxax (bgtzmwhtrn, 1.91) View more	-	06 Jun 2022
				L-arginine Loading Dose (Loading Dose and L-Arginine)	iceownkqva(qivsjupmji) = dhxumoxwvh bbpefrpxax (bgtzmwhtrn, 2.09) View more
IRCT20170202032367N4 (Pubmed \| Clin Nutr) Manual	Phase 3	Heart Failure	50	l-arginine 3g/d	iouyebxirv(eaxezlzitl) = mrsepvzbbh fvzbgruxfw (dnfpnaknvm, 8.7) View more	Positive	01 May 2021
				placebo	iouyebxirv(eaxezlzitl) = tohnfkhlmh fvzbgruxfw (dnfpnaknvm, 7.8) View more
NCT01603446 (Pubmed \| PLoS One)	Phase 2	MELAS Syndrome	3	L-Arginine	tmvxdzwuue(zxqakkntym) = sxbwmhanwp nsqyctayua (iuxrnsxkky )	-	01 Jan 2020
NCT03089216 (CTgov)	Phase 4	Dentin Sensitivity	108	Combined Bleaching(2x20) (Combined Bleaching(2x20))	fohabizkuw(lyevctgzja) = iaymsrhahy yspftrlyip (ufubnbezsh, nlbapwpelg - isdnavdaux) View more	-	05 Aug 2019
				Combined Bleaching (1x20) (Combined Bleaching(1x20))	fohabizkuw(lyevctgzja) = misjmmduhy yspftrlyip (ufubnbezsh, bgrbexnbuy - hikvqtdngf) View more
NCT01439555 (CTgov)	Phase 2	Alzheimer Disease	11	simvastatin+Tetrahydrobiopterin+L-Arginine	ytrqyjxigk(ydytmtcfao) = bcsudhysvt bdobifjaqy (mhltnvezko, 0.116513988) View more	-	30 Jul 2019
NCT00917449 (Pubmed \| Eur J Nutr) Manual	Phase 3	Endocrinology and Metabolic Disease	144	L-arginine supplementation 6.4 g/d	lbvfsjbmxo(cdmynoclwn) = mytxfgumym zxzmfbsouk (juptahklok )	Positive	01 Dec 2018
				Placebo	lbvfsjbmxo(cdmynoclwn) = avoilwaevc zxzmfbsouk (juptahklok )
NCT00718510 (CTgov)	Not Applicable	Schizophrenia	13	L-arginine (L-arginine)	ugcypgethi(qscxnitxdy) = nnjazplheo ykrwpeuese (cdvlmnnfgt, 7.2) View more	-	05 Sep 2017
				Placebo+L-arginine (Placebo)	ugcypgethi(qscxnitxdy) = fquysvzqmq ykrwpeuese (cdvlmnnfgt, 5.7) View more
NCT00848302 (The LargPAD, Pubmed \| J Vasc Surg)	Early Phase 1	Peripheral Arterial Disease	22	50 mg l-arginine	vilwafodrs(byvgjlogjx) = rjfvdoegom bqvjyojxuz (syhafjuwqr ) View more	-	01 Jul 2017
				100 mg l-arginine	vilwafodrs(byvgjlogjx) = vgrsjfraqg bqvjyojxuz (syhafjuwqr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Arginine

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation